CO2021013166A2 - Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria - Google Patents

Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria

Info

Publication number
CO2021013166A2
CO2021013166A2 CONC2021/0013166A CO2021013166A CO2021013166A2 CO 2021013166 A2 CO2021013166 A2 CO 2021013166A2 CO 2021013166 A CO2021013166 A CO 2021013166A CO 2021013166 A2 CO2021013166 A2 CO 2021013166A2
Authority
CO
Colombia
Prior art keywords
pyrazino
hexahydro
treatment
autoimmune disease
pyrazine compounds
Prior art date
Application number
CONC2021/0013166A
Other languages
English (en)
Spanish (es)
Inventor
Hong Shen
Lue Dai
Buyu Kou
Yongfu Liu
Yafei Liu
Zhiwei Zhang
Linuo Zhu
Wei Zhu
Fabian Dey
Haixia Liu
Zhisen Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2021013166A2 publication Critical patent/CO2021013166A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CONC2021/0013166A 2019-04-09 2021-09-30 Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria CO2021013166A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019081900 2019-04-09
CN2019121598 2019-11-28
CN2020078225 2020-03-06
PCT/EP2020/059831 WO2020207991A1 (en) 2019-04-09 2020-04-07 Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
CO2021013166A2 true CO2021013166A2 (es) 2021-12-10

Family

ID=70228042

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0013166A CO2021013166A2 (es) 2019-04-09 2021-09-30 Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria

Country Status (19)

Country Link
US (1) US20220340597A1 (cg-RX-API-DMAC10.html)
EP (1) EP3953356B1 (cg-RX-API-DMAC10.html)
JP (1) JP7692838B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210149163A (cg-RX-API-DMAC10.html)
CN (1) CN113710672B (cg-RX-API-DMAC10.html)
AU (1) AU2020272467A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021020297A2 (cg-RX-API-DMAC10.html)
CA (1) CA3135129A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021002621A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021013166A2 (cg-RX-API-DMAC10.html)
CR (1) CR20210513A (cg-RX-API-DMAC10.html)
IL (1) IL286870A (cg-RX-API-DMAC10.html)
MA (1) MA55594A (cg-RX-API-DMAC10.html)
MX (1) MX2021012223A (cg-RX-API-DMAC10.html)
PE (1) PE20212178A1 (cg-RX-API-DMAC10.html)
PH (1) PH12021552533A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202110401WA (cg-RX-API-DMAC10.html)
TW (1) TW202104230A (cg-RX-API-DMAC10.html)
WO (1) WO2020207991A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114599652B (zh) * 2019-10-31 2024-07-12 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物
WO2021094301A1 (en) * 2019-11-12 2021-05-20 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease
EP4061816A1 (en) 2019-11-19 2022-09-28 F. Hoffmann-La Roche AG Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
US12503471B2 (en) 2019-11-19 2025-12-23 Hoffmann-La Roche Inc. Triazatricycle compounds for the treatment of autoimmune disease
US12478621B2 (en) 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CN114761406B (zh) 2019-12-03 2024-04-19 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物
JP2023533807A (ja) * 2020-07-14 2023-08-04 エフ. ホフマン-ラ ロシュ アーゲー 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2663555T3 (en) * 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
HRP20171981T1 (hr) 2012-09-14 2018-02-09 F. Hoffmann - La Roche Ag Derivati pirazolkarboksamida kao taar modulatora za uporabu u liječenju nekoliko poremećaja poput depresije, dijabetesa i parkinsonove bolesti
US9643967B2 (en) * 2013-12-13 2017-05-09 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
JP2021527100A (ja) * 2018-06-13 2021-10-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 自己免疫疾患の処置のためのピリジニルヘテロシクリル化合物
CN112752755A (zh) * 2018-09-27 2021-05-04 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的杂环基化合物

Also Published As

Publication number Publication date
AU2020272467A1 (en) 2021-10-14
WO2020207991A1 (en) 2020-10-15
PH12021552533A1 (en) 2022-06-20
PE20212178A1 (es) 2021-11-09
EP3953356C0 (en) 2023-07-26
EP3953356B1 (en) 2023-07-26
SG11202110401WA (en) 2021-10-28
BR112021020297A2 (pt) 2021-12-14
CN113710672A (zh) 2021-11-26
IL286870A (en) 2021-10-31
EP3953356A1 (en) 2022-02-16
JP7692838B2 (ja) 2025-06-16
CN113710672B (zh) 2025-01-03
MA55594A (fr) 2022-02-16
CR20210513A (es) 2021-11-02
MX2021012223A (es) 2021-11-03
CA3135129A1 (en) 2020-10-15
TW202104230A (zh) 2021-02-01
KR20210149163A (ko) 2021-12-08
JP2022527588A (ja) 2022-06-02
CL2021002621A1 (es) 2022-05-13
US20220340597A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
ECSP22046699A (es) Inhibidores de kras g12c
DOP2019000030A (es) Inhibidores de cdk2/4/6
ECSP22038509A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
CO2022004723A2 (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
MX2019003724A (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
CL2022001741A1 (es) Compuestos cíclicos y métodos de uso de estos
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CO2020014677A2 (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes
CO2022002336A2 (es) Compuestos heterocíclicos
MX2021000462A (es) Derivados de pirrolo-[1,2-b]-piridazina.
CL2025000161A1 (es) Compuestos cíclicos y métodos de utilización de estos.
PA8589801A1 (es) Aminoalcoxiindoles
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
CO2024006398A2 (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
CU24543B1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX2020002015A (es) Sales de un compuesto y sus formas cristalinas.
AR131945A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
CO2025001103A2 (es) Derivados de tetrahidrotiazepina bicíclicos
AR116989A1 (es) Hemiadipato de 5,8-dimetil-2-[2-(1-metil-4-fenil-1h-imidazol-2-il)etil][1,2,4]triazolo[1,5-a]pirazina